Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors

被引：55

作者：

McGee, J. ^{[1
]}

Bookman, M. ^{[2
]}

Harter, P. ^{[3
]}

Marth, C. ^{[4
]}

McNeish, I. ^{[5
]}

Moore, K. N. ^{[2
]}

Poveda, A. ^{[6
]}

Hilpert, F. ^{[3
]}

Hasegawa, K. ^{[7
]}

Bacon, M. ^{[8
]}

Gatsonis, C. ^{[9
]}

Brand, A. ^{[10
]}

Kridelka, F. ^{[11
]}

Berek, J. ^{[12
]}

Ottevanger, N. ^{[13
]}

Levy, T. ^{[14
]}

Silverberg, S. ^{[15
]}

Kim, B. -G. ^{[16
]}

Hirte, H. ^{[1
]}

Okamoto, A. ^{[15
]}

Stuart, G. ^{[1
]}

Ochiai, K. ^{[15
]}

机构：

[1] CCTG, Kingston, ON, Canada

[2] GOG, Philadelphia, PA USA

[3] AGO, Wiesbaden, Germany

[4] AGO AU, Innsbruck, Austria

[5] MRC NCRI, London, England

[6] GEICO, Madrid, Spain

[7] GOTIC, Saitama, Japan

[8] GCIG, Kingston, ON, Canada

[9] ECOG ACRIN, Philadelphia, PA USA

[10] ANZGOG, Camperdown, NSW, Australia

[11] BGOG, Leuven, Belgium

[12] COGi, Stanford, CA USA

[13] EORTC GCG, Brussels, Belgium

[14] ISGO, Holon, Israel

[15] JGOG, Tokyo, Japan

[16] KGOG, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷 / 04期

关键词：

ovarian cancer; consensus conference; GCIG; individualized therapy; recommendations; RECURRENT EPITHELIAL OVARIAN; GRADE SEROUS CARCINOMA; NEOADJUVANT CHEMOTHERAPY; PERITONEAL CARCINOMA; CLINICAL-TRIALS; FALLOPIAN-TUBE; DOUBLE-BLIND; STAGE-III; SURGICAL CYTOREDUCTION; AGGRESSIVE SURGERY;

D O I：

10.1093/annonc/mdx010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

This manuscript reports the consensus statements regarding the design and conduct of clinical trials in patients with newly diagnosed and recurrent epithelial ovarian cancer (EOC), following deliberation at the Fifth Ovarian Cancer Consensus Conference (OCCC), held in Tokyo in November 2015. Three important questions were identified for discussion prior to the meeting and achieved consensus during the meeting: (i) What are the most important factors to be evaluated prior to initial therapy? (ii) What are the most important factors to be evaluated specifically in recurrent disease? (iii) Are there specific considerations for special patient subpopulations? In addition, we report a list of important unmet needs compiled during the consensus process, which is intended to guide future research initiatives.

引用

页码：702 / 710

页数：9

共 88 条

[1]

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [J].

Abkevich, V. ;

Timms, K. M. ;

Hennessy, B. T. ;

Potter, J. ;

Carey, M. S. ;

Meyer, L. A. ;

Smith-McCune, K. ;

Broaddus, R. ;

Lu, K. H. ;

Chen, J. ;

Tran, T. V. ;

Williams, D. ;

Iliev, D. ;

Jammulapati, S. ;

FitzGerald, L. M. ;

Krivak, T. ;

DeLoia, J. A. ;

Gutin, A. ;

Mills, G. B. ;

Lanchbury, J. S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1776-1782

[2]

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[3]

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary [J].

Ahmed, Ashour Ahmed ;

Etemadmoghadam, Dariush ;

Temple, Jillian ;

Lynch, Andy G. ;

Riad, Mohamed ;

Sharma, Raghwa ;

Stewart, Colin ;

Fereday, Sian ;

Caldas, Carlos ;

DeFazio, Anna ;

Bowtell, David ;

Brenton, James D. .

JOURNAL OF PATHOLOGY, 2010, 221 (01) :49-56

[4]

A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model [J].

Aletti, Giovanni D. ;

Santillan, Antonio ;

Eisenhauer, Eric L. ;

Hu, Jae ;

Aletti, Giacomo ;

Podratz, Karl C. ;

Bristow, Robert E. ;

Chi, Dennis S. ;

Cliby, William A. .

GYNECOLOGIC ONCOLOGY, 2007, 107 (01) :99-106

[5]

Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment [J].

Aletti, Giovanni D. ;

Eisenhauer, Eric L. ;

Santillan, Antonio ;

Axtell, Allison ;

Aletti, Giacomo ;

Holschneider, Christine ;

Chi, Dennis S. ;

Bristow, Robert E. ;

Cliby, William A. .

GYNECOLOGIC ONCOLOGY, 2011, 120 (01) :23-28

[6]

Quality Improvement in the Surgical Approach to Advanced Ovarian Cancer: The Mayo Clinic Experience [J].

Aletti, Giovanni D. ;

Dowdy, Sean C. ;

Gostout, Bobbie S. ;

Jones, Monica B. ;

Stanhope, Robert C. ;

Wilson, Timothy O. ;

Podratz, Karl C. ;

Cliby, William A. .

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2009, 208 (04) :614-620

[7]

[Anonymous], 2015, J CLIN ONCOL, DOI DOI 10.1200/JCO.2015.33.15_SUPPL.5508

[8]

Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[9]

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma [J].

Boehm, Steffen ;

Faruqi, Asma ;

Said, Ian ;

Lockley, Michelle ;

Brockbank, Elly ;

Jeyarajah, Arjun ;

Fitzpatrick, Amanda ;

Ennis, Darren ;

Dowe, Thomas ;

Santos, Jennifer L. ;

Cook, Linda S. ;

Tinker, Anna V. ;

Le, Nhu D. ;

Gilks, C. Blake ;

Singh, Naveena .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (22) :2457-U73

[10]

Bookman MA, 2014, JNCI-J NATL CANCER I, V106, P1

← 1 2 3 4 5 6 7 8 9 →